Author: admin

Julz at BioFIT panel discussion on seed funding

Julz will be attending BioFIT Conference in Lille, France on Dec 4-5, 2018. BioFIT conferences are dedicated to bring academia and industry together. It has become the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. For more information, please visit… Read More

Julz at Biotech and Money Investival Showcase 2018

LSX (formerly Biotech and Money) connects corporates to capital. The Investival Showcase displays the latest innovative and investable private and public life science opportunities to the investor community. In exclusive partnership with Jefferies LLC, the Investival Showcase spans four tracks and will feature the most exciting companies across key sub-sectors… Read More

Julz at RESI in NYC

Julz is attending the RESI Conference in New York City on November 5th, 2018. Julz Co is an investment management company focused on the health care industry with an emphasis on therapeutics, medical devices, digital healthcare and services. The company has offices in Chapel Hill, North Carolina, USA and Suzhou,… Read More

Julz will be at RESI in Boston in September

Julz is attending the RESI Conference in Boston on September 6th, 2018. Julz Co is an investment management company focused on the health care industry with an emphasis on therapeutics, medical devices, digital healthcare and services. The company has offices in Chapel Hill, North Carolina, USA and Suzhou, China. Julz… Read More

CALCIVIS Raises £3.15 Million to Fund PMA Approval of the CALCIVIS® Imaging System Ahead of a Planned US Launch in 2019

CALCIVIS, a medical devices company focused on revolutionising the management of tooth decay and enabling preventive dentistry, announces it has closed a £3.15 million equity funding round from existing investors Archangel Investors, Julz and the Scottish Investment Bank. The proceeds will be used to support the completion of the FDA's… Read More